Development

Articles

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program. 

Ashland Injectable Pharmaceutical Excipient Accepted into FDA Novel Excipient Review Pilot Program

Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.

Roquette Launches Next-Generation Direct Compression Solutions

Roquette’s acquisition of Crest Cellulose is designed to reinforce its presence in India and other countries in Asia.

Roquette Acquires Indian Excipient Manufacturer

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

Lubrizol Launches Apisolex Technology 

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

Developing Excipients for High-Concentration Biologic Formulations

Roquette is investing €25 million at its site in Lestrem, France to strengthen its position in the polyols market.

Roquette Invests €25 million for Polyols at its Site in Lestrem, France

Careful selection is essential for achieving viscosity reduction without protein destabilization.

Excipients for High-Concentration Biologics

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Subunit Vaccines and the Fight Against COVID-19

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients 

DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services. 